Barclays’s Gyre Therapeutics GYRE Stock Holding History

Barclays’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-1,333	Closed	-$117K	–	7227
2018 Q2	$117K	Buy	+1,333	New	+$234K	﹤0.01%	5135

Other funds holding GYRE

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Barclays's GYRE Position: Q1 2026 in Review

Barclays reduced its Gyre Therapeutics (GYRE) stake by 88% in Q1 2026, selling an estimated $126K and leaving 2,300 shares worth $16K. The position accounts for ﹤0.01% of the portfolio, ranked #4619.

Barclays first reported a position in GYRE in Q2 2013 and has held it in 40 quarters since. The position peaked at $454K in Q2 2018. 56 funds tracked by Wall St. Rank hold GYRE as of Q1 2026.

Barclays held 2,300 shares of Gyre Therapeutics worth $16K as of Q1 2026.
Barclays sold 16,231 Gyre Therapeutics shares in Q1 2026, an estimated $126K.
Gyre Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4619 holding.
Barclays first reported a position in Gyre Therapeutics in Q2 2013 and has held it in 40 quarters since.
Barclays's Gyre Therapeutics position peaked at $454K in Q2 2018.
56 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.